Robotic mitral valve repair-the Bruxelles experience.
Robotic mitral repair
mitral regurgitation robotic repair
robot-assisted mitral repair
robotic mitral surgery
Journal
Annals of cardiothoracic surgery
ISSN: 2225-319X
Titre abrégé: Ann Cardiothorac Surg
Pays: China
ID NLM: 101605877
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
26
06
2022
accepted:
05
10
2022
entrez:
9
12
2022
pubmed:
10
12
2022
medline:
10
12
2022
Statut:
ppublish
Résumé
Although the use of the surgical robot facilitates less invasive mitral valve surgery, both real and perceived limitations have slowed the application of this technology. Aim of the present investigation was to report the early and long-term results of robotic mitral valve repair in a single institution over a 10-year period. Between March 2012 and May 2022, a total of 278 consecutive patients underwent robotically assisted mitral valve repair at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). Indications have evolved over time allowing the treatment of complex mitral valve lesions. Clinical and echocardiographic follow-up were 97.8% and 86.1% complete, respectively. Mean age of the study population was 57.8±11.9 years and 221/278 (79.5%) patients were male. Despite being asymptomatic or mildly symptomatic [New York Heart Association (NYHA) class I-II], most of the patients presented with severe mitral regurgitation (MR). Degenerative mitral valve disease was the most common cause of MR. All patients underwent successful mitral valve repair using different techniques, and 25/278 (9.0%) had one or more concomitant procedures associated. The mean cardio-pulmonary bypass and aortic cross clamp times were 153±37 and 106±25 minutes, respectively. There was no operative or in-hospital mortality. Overall survival rate was 97.8%±3.2%, 95.8%±3.2% and 93.7%±3.0% at 3, 7 and 10 years. One early (0.4%) reoperation with re-repair was recorded for ring disruption, while late mitral valve re-repair was necessary in 4/279 (1.4%) patients for recurrent severe MR in three of them and mitral endocarditis in one. The overall freedom from mitral valve reoperation was 98.1%±1.0% at 3, 7 and 10 years. Overall freedom from MR (grade 2+ or more) was 91.7%±3.2%, 77.8%±4.8% and 67.1%±9.2% at 3, 7 and 10 years, respectively. Robotic mitral valve repair is safe and is associated with excellent clinical and echocardiographic results. The use of robotic technologies allows, after an appropriate learning curve, to reproduce all conventional techniques to treat MR, regardless of the complexity of the valve lesion.
Sections du résumé
Background
UNASSIGNED
Although the use of the surgical robot facilitates less invasive mitral valve surgery, both real and perceived limitations have slowed the application of this technology. Aim of the present investigation was to report the early and long-term results of robotic mitral valve repair in a single institution over a 10-year period.
Methods
UNASSIGNED
Between March 2012 and May 2022, a total of 278 consecutive patients underwent robotically assisted mitral valve repair at the Cliniques Universitaires Saint-Luc (Brussels, Belgium). Indications have evolved over time allowing the treatment of complex mitral valve lesions. Clinical and echocardiographic follow-up were 97.8% and 86.1% complete, respectively.
Results
UNASSIGNED
Mean age of the study population was 57.8±11.9 years and 221/278 (79.5%) patients were male. Despite being asymptomatic or mildly symptomatic [New York Heart Association (NYHA) class I-II], most of the patients presented with severe mitral regurgitation (MR). Degenerative mitral valve disease was the most common cause of MR. All patients underwent successful mitral valve repair using different techniques, and 25/278 (9.0%) had one or more concomitant procedures associated. The mean cardio-pulmonary bypass and aortic cross clamp times were 153±37 and 106±25 minutes, respectively. There was no operative or in-hospital mortality. Overall survival rate was 97.8%±3.2%, 95.8%±3.2% and 93.7%±3.0% at 3, 7 and 10 years. One early (0.4%) reoperation with re-repair was recorded for ring disruption, while late mitral valve re-repair was necessary in 4/279 (1.4%) patients for recurrent severe MR in three of them and mitral endocarditis in one. The overall freedom from mitral valve reoperation was 98.1%±1.0% at 3, 7 and 10 years. Overall freedom from MR (grade 2+ or more) was 91.7%±3.2%, 77.8%±4.8% and 67.1%±9.2% at 3, 7 and 10 years, respectively.
Conclusions
UNASSIGNED
Robotic mitral valve repair is safe and is associated with excellent clinical and echocardiographic results. The use of robotic technologies allows, after an appropriate learning curve, to reproduce all conventional techniques to treat MR, regardless of the complexity of the valve lesion.
Identifiants
pubmed: 36483615
doi: 10.21037/acs-2022-rmvs-20
pii: acs-11-06-589
pmc: PMC9723534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
589-595Informations de copyright
2022 Annals of Cardiothoracic Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Ann Thorac Surg. 2012 Jul;94(1):38-42; discussion 43
pubmed: 22560967
Circulation. 1995 Feb 15;91(4):1022-8
pubmed: 7850937
Semin Thorac Cardiovasc Surg. 2022 Winter;34(4):1220-1229
pubmed: 34597795
Circulation. 2003 Sep 9;108 Suppl 1:II48-54
pubmed: 12970208
Ann Thorac Surg. 2009 Oct;88(4):1180-4
pubmed: 19766803
J Am Coll Cardiol. 2010 Aug 3;56(6):455-62
pubmed: 20670754
Eur J Cardiothorac Surg. 2008 Oct;34(4):760-5
pubmed: 18586512
Eur J Cardiothorac Surg. 2006 Mar;29(3):362-6
pubmed: 16423535
J Thorac Cardiovasc Surg. 2008 Aug;136(2):436-41
pubmed: 18692654
Ann Cardiothorac Surg. 2017 Jan;6(1):1-8
pubmed: 28203535
J Thorac Cardiovasc Surg. 1998 Nov;116(5):734-43
pubmed: 9806380
J Thorac Cardiovasc Surg. 2018 Jan;155(1):82-91.e2
pubmed: 28893396
J Thorac Cardiovasc Surg. 2011 Jan;141(1):72-80.e1-4
pubmed: 21093881
J Thorac Cardiovasc Surg. 2010 Mar;139(3):628-33
pubmed: 20038479
Circulation. 2001 Sep 18;104(12 Suppl 1):I1-I7
pubmed: 11568020
Eur J Cardiothorac Surg. 2008 Apr;33(4):523-8
pubmed: 18313319
Circulation. 2015 Nov 24;132(21):1961-8
pubmed: 26481775
J Card Surg. 2022 Aug;37(8):2266-2277
pubmed: 35510407
Ann Thorac Surg. 2002 Sep;74(3):660-3; discussion 663-4
pubmed: 12238820
Interact Cardiovasc Thorac Surg. 2017 Jul 1;25(1):62-67
pubmed: 28369386
J Thorac Cardiovasc Surg. 2008 Apr;135(4):885-93, 893.e1-2
pubmed: 18374775
Eur J Cardiothorac Surg. 2018 Oct 1;54(4):774-780
pubmed: 29547941
Ann Surg. 2004 Sep;240(3):529-34; discussion 534
pubmed: 15319724
Ann Cardiothorac Surg. 2015 May;4(3):230-7
pubmed: 26309824
Eur J Cardiothorac Surg. 2021 Jan 4;59(1):180-186
pubmed: 32776150